Dermira, Inc.

Dermira, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older. It also develops lebrikizumab, a novel injectable humanized monoclonal antibody targeting interleukin 13 that is in Phase IIb clinical trial for the treatment of moderate-to-severe atopic dermatitis; and early-stage research and development programs in other areas of dermatology. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in August 2012. Dermira, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California. Dermira, Inc. operates as a subsidiary of Eli Lilly and Company.